Reference
Ngu S-F, et al. A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report. Cancer Drug Resistance 5: 662-666, No. 3, 22 Jun 2022. Available from: URL: https://cdrjournal.com/article/view/4784
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1955, 36 (2023). https://doi.org/10.1007/s40278-023-38283-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-38283-3